Oramed Pharmaceuticals Inc. (ORMP) stock

ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30

$3.71−0.32 (-7.94%)

Close on Nov 13, 2026Market cap $154.33MP/E 1.1Yield 6.74%

Oramed Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Oramed Pharmaceuticals's total debt was $32.03M at Mar 31, 2024. For fiscal 2023 it was $51.01M, up 1787.3% from the year before.

Period	Period end	Value	Change
FY2023	Dec 31, 2023	$51.01M	+1787.3%
FY2019	Aug 31, 2019	$2.70M	+10.4%
FY2018	Aug 31, 2018	$2.45M	–

Change is against the same quarter a year earlier.

Periods

Period	Period end	Value	Change
Q1 FY2024CQ1 2024	Mar 31, 2024	$32.03M	+1208.0%
Q4 FY2023CQ4 2023	Dec 31, 2023	$51.01M	–
Q3 FY2023CQ3 2023	Sep 30, 2023	$75.36M	–
Q4 FY2019CQ3 2019	Aug 31, 2019	$2.70M	–
Q4 FY2018CQ3 2018	Aug 31, 2018	$2.45M	–

Parsed from the XBRL in Oramed Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-12 reverse split on Jan 23, 2013
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ORMP.

Operating margin-810.1% · median -2093.7%

Net margin7244.3% · median -1351.3%

Advertisement
300 × 250

See a number that looks wrong?